Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$97.96 USD

97.96
1,373,027

-0.36 (-0.37%)

Updated Jun 5, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 248)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

by Zacks Equity Research

The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).

Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery

by Zacks Equity Research

Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.

Here's Why You Should Retain HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) strength in HSAs raises optimism about the stock.

Cencora (COR) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research

by Zacks Equity Research

Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.

Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges

by Zacks Equity Research

Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.

High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio

by Zacks Equity Research

High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.

Chemed (CHE) Reaches a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.

Labcorp (LH) Presents New Research on Precision Diagnostics

by Zacks Equity Research

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

by Zacks Equity Research

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats

by Zacks Equity Research

PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.

The Zacks Analyst Blog Highlights Atmos Energy, Balchem, Cardinal Health, Casey's and Colgate-Palmolive

by Zacks Equity Research

Atmos Energy, Balchem, Cardinal Health, Casey's and Colgate-Palmolive are included in this Analyst Blog.

Here's Why You Should Buy Insulet (PODD) Stock Right Now

by Zacks Equity Research

Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.

Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM

by Zacks Equity Research

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow

by Zacks Equity Research

GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.

Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

by Zacks Equity Research

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Intuitive Surgical's (ISRG) Da Vinci 5 Receives FDA Approval

by Zacks Equity Research

Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.

Waters (WAT) Boosts Portfolio Strength With Rheo-IS Accessory

by Zacks Equity Research

Waters (WAT) unveils Rheo-IS accessory for its TA Instruments Discovery Hybrid Rheometers, bolstering its overall portfolio.

Labcorp (LH) Expands Strategic Alliances, Test Sales Fall

by Zacks Equity Research

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.